EUVIMEDEUVIMED entdecken
Open Access

Reversal of Experimental Autoimmune Diabetes With an sCD39/Anti-CD3 Treatment

Carmen Fotino iD, R Damaris Molano, Moufida Ben Nasr, Oliver Umland, Christopher A Fraker, Ulisse Ulissi, Hari Baskar Balasubramanian, Maria Elena Lunati, Vera Usuelli, Andy Joe Seelam, Salma Ayman Khalefa, Christian La Sala und 6 weitere

Diabetes · 2023

DOI: 10.2337/db23-0178 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, 2023. Verfasst von Carmen Fotino und 17 weiteren Autor:innen. Beteiligte Einrichtung: Cell Transplant Center, Diabetes Research Institute, University of Miami, Miami, FL. Hauptthemen laut MEDLINE: Antigens, CD, Apyrase, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Fondazione Diabete Ricerca (FO.DI.RI) Società Italiana di Diabetologia (SID) fellowship, Italian Ministry of Health, Diabetes Research Institute Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extracellular (e)ATP, a potent proinflammatory molecule, is released by dying/damaged cells at the site of inflammation and is degraded by the membrane ectonucleotidases CD39 and CD73. In this study, we sought to unveil the role of eATP degradation in autoimmune diabetes. We then assessed the effect of soluble CD39 (sCD39) administration in prevention and reversal studies in NOD mice as well as in mechanistic studies. Our data showed that eATP levels were increased in hyperglycemic NOD mice compared with prediabetic NOD mice. CD39 and CD73 were found expressed by both α- and β-cells and by different subsets of T cells. Importantly, prediabetic NOD mice displayed increased frequencies of CD3+CD73+CD39+ cells within their pancreata, pancreatic lymph nodes, and spleens. The administration of sCD39 into prediabetic NOD mice reduced their eATP levels, abrogated the proliferation of CD4+- and CD8+-autoreactive T cells, and increased the frequency of regulatory T cells, while delaying the onset of T1D. Notably, concomitant administration of sCD39 and anti-CD3 showed a strong synergism in restoring normoglycemia in newly hyperglycemic NOD mice compared with monotherapy with anti-CD3 or with sCD39. The eATP/CD39 pathway plays an important role in the onset of T1D, and its targeting might represent a potential therapeutic strategy in T1D. Article Highlights

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, CDApyraseDiabetes Mellitus, Type 1AnimalsFemaleMice5'-NucleotidaseAdenosine TriphosphateCD3 ComplexDiabetes Mellitus, ExperimentalInsulin-Secreting CellsMice, Inbred NODT-Lymphocytes, Regulatory

Substanzen

5'-NucleotidaseAdenosine TriphosphateAntigens, CDApyraseCD3 ComplexCD39 antigen

Autor:innen und Institutionen

  • Cell Transplant Center, Diabetes Research Institute, University of Miami, Miami, FL.
  • International Center for T1D, Pediatric Clinical Research Center "Romeo ed Enrica Invernizzi," Department of Biomedical and Clinical Science L. Sacco, University of Milan, Milan, Italy.
  • Nephrology Division, Boston Children's Hospital, Harvard Medical School, Boston, MA.
  • Division of Cellular Transplantation, DeWitt Daughtry Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL.
  • Division of Endocrinology, Azienda Socio-Sanitaria Territoriale (ASST) Fatebenefratelli-Sacco, Milan, Italy.
  • Division of Endocrinology, Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL.

ORCID-Profile: Carmen Fotino, Paolo Fiorina, Antonello Pileggi

Förderung

  • Fondazione Diabete Ricerca (FO.DI.RI) Società Italiana di Diabetologia (SID) fellowship
  • Italian Ministry of Health
  • Diabetes Research Institute Foundation

Zitieren

APA

Fotino, C., Molano, R. D., Ben Nasr, M., Umland, O., Fraker, C. A., Ulissi, U., Balasubramanian, H. B., Lunati, M. E., Usuelli, V., Seelam, A. J., Khalefa, S. A., La Sala, C., Gimeno, J., Mendez, A. J., Ricordi, C., Bayer, A. L., Fiorina, P., & Pileggi, A. (2023). Reversal of Experimental Autoimmune Diabetes With an sCD39/Anti-CD3 Treatment. Diabetes. https://doi.org/10.2337/db23-0178

Vancouver

Fotino C, Molano RD, Ben Nasr M, Umland O, Fraker CA, Ulissi U, et al. Reversal of Experimental Autoimmune Diabetes With an sCD39/Anti-CD3 Treatment. Diabetes. 2023. doi:10.2337/db23-0178

BibTeX
@article{Fotino2023,
  author = {Fotino, Carmen and Molano, R Damaris and Ben Nasr, Moufida and Umland, Oliver and Fraker, Christopher A and Ulissi, Ulisse and Balasubramanian, Hari Baskar and Lunati, Maria Elena and Usuelli, Vera and Seelam, Andy Joe and Khalefa, Salma Ayman and La Sala, Christian and Gimeno, Jennifer and Mendez, Armando J and Ricordi, Camillo and Bayer, Allison L and Fiorina, Paolo and Pileggi, Antonello},
  title = {Reversal of Experimental Autoimmune Diabetes With an sCD39/Anti-CD3 Treatment},
  journal = {Diabetes},
  year = {2023},
  doi = {10.2337/db23-0178}
}
Kostenlos starten →